News
Apr. 8, 2025 — Researchers estimated that smoke from wildfires and prescribed burns caused $200 billion in health damages in 2017, and that these were associated with 20,000 premature deaths ...
Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...
Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...
Novo's obesity therapy Wegovy is significantly expanding the obesity treatment market given its strong efficacy and is poised to remain a key drug in the market until patent expiration in 2032.
The Lihir Kokoda Track Foundation FODE program on Lihir Island, New Ireland Province successfully witnessed its 2nd batch graduation day with flying colours last week at the Lihir Meri Development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results